logo
Share SHARE
FONT-SIZE Plus   Neg

Lonza, Agennix Ink Deal For Production Of Talactoferrin - Quick Facts

Lonza Group AG (LZAGF.PK) said it entered into an agreement with Agennix AG for the production of Agennix's first-in-class oral Dendritic Cell Mediated Immunotherapy, talactoferrin, currently in Phase III testing for the treatment of non-small cell lung cancer.

As per the agreement, Lonza will produce commercial material at its microbial manufacturing facility in Kourim, Czech Republic. Lonza stated that the agreement initiates the process needed to be able to ultimately seek approval for Lonza as a second manufacturer of talactoferrin after the initial commercial launch.

Rajesh Malik, chief medical officer and Management Board member of Agennix, said, "We are pleased to enter this agreement with Lonza, which has extensive experience manufacturing biologics on a commercial scale. In anticipation of positive Phase III data and a potential product approval, it is important that we have more than one manufacturer in place to ensure we can meet anticipated commercial demand and that we have security of supply."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The holiday throng seeking to take a flight out to their preferred destinations at the at New York's Kennedy International Airport ahead of the Memorial Day holiday were in for a rude shock. Technology played a spoilsport, as a computer system broke down Sunday evening at a terminal, causing flight delays and cancellations that resulted in manual check-in process for thousands of holiday passeng The month of May saw the FDA greenlight 5 new drugs, including 1 new molecular entity, and surprisingly turn down 1 drug candidate, whose approval was considered a no-brainer by some experts. Lab equipment maker Thermo Fisher Scientific Inc. has agreed to acquire electron microscope maker FEI Co. for about $4.2 billion in cash, the two companies said Friday. Thermo Fisher noted that FEI's electron microscopy platform will complement its own mass spectrometry systems to accelerate advancements in structural biology.
comments powered by Disqus
Follow RTT